Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics (APGE)
NASDAQ:APGE
APGE Stock Chart & Stats
$77.48
-$0.82(-1.65%)
At close: 4:00 PM EST
$77.48
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$26.20 - $80.99
Previous CloseN/A
Volume109.80K
Average Volume (3M)891.51K
Market Cap
$5.29B
Enterprise Value$1.82B
Total Cash (Recent Filing)$527.29M
Total Debt (Recent Filing)$9.85M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 10, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding54,833,588
10 Day Avg. Volume827,490
30 Day Avg. Volume891,506
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.49
Price to Sales (P/S)0.00
P/FCF Ratio-14.51
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.54K
Enterprise Value/Ebitda-6.59
Forecast
1Y Price Target
$102.50Price Target Upside32.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Biomarker ResponsePhase 1b produced a strong and sustained reduction in the airway inflammation biomarker FeNO after a single injection, supporting the potential for long‑acting efficacy and less frequent maintenance dosing that could attract patient and physician preference.
Expanded Commercial OpportunityAnalyst highlights potential for dual labeling in asthma and atopic dermatitis, which would broaden prescriber reach to pulmonologists and allergists and materially increase the drug’s market opportunity versus single‑indication competitors.
Favorable Safety ProfileNo cases of conjunctivitis or severe treatment‑emergent adverse events were reported in Phase 1b, indicating a safety profile that could simplify regulatory review and support broader clinical development.
Bears Say
Research Objectivity ConcernsAnalyst disclosure of potential conflicts of interest could cast doubt on the objectivity of positive recommendations and influence how investors interpret the reported data and target revisions.
Small And Imbalanced Trial DatasetThe Phase 1b dataset was small and showed imbalance in background asthma medications, limiting confidence in efficacy signals and requiring larger, better‑controlled trials to validate findings.
Uncertain Translation To Clinical BenefitReductions in biomarkers may not translate into meaningful symptom or lung function improvements for patients, so the magnitude of real clinical benefit remains uncertain until outcome trials are completed.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $26.20 and its highest was $80.99 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $5.29B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 57 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.175 by $0.065.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 54,833,588 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.175. Following the earnings report the stock price went up 3.765%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.50 (32.29% Upside)
$102.50 (32.29% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 776.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.44%
12-Months-Change
Fundamentals
Return on Equity
-38.41%
Trailing 12-Months
Asset Growth
-19.34%
Trailing 12-Months
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$102.50
▲(32.29% Upside)
Technical Analysis
Agios Pharma
―
Ocular Therapeutix
―
Galapagos
―
Liquidia Technologies
―
IDEAYA Biosciences
―
Ownership Overview
Currently, No data available
---